阿伐替尼对新诊断的慢性粒细胞白血病患者安全有效。 - Suppr | 超能文献

Asciminib is safe and effective in patients with newly diagnosed CML.

作者信息

Romero Diana

机构信息

Nature Reviews Clinical Oncology, .

出版信息

Nat Rev Clin Oncol. 2024 Aug;21(8):566. doi: 10.1038/s41571-024-00919-6.

DOI:10.1038/s41571-024-00919-6

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Asciminib is safe and effective in patients with newly diagnosed CML.阿伐替尼对新诊断的慢性粒细胞白血病患者安全有效。

Nat Rev Clin Oncol. 2024 Aug;21(8):566. doi: 10.1038/s41571-024-00919-6.

2

Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.阿西替尼：一线治疗慢性髓性白血病的新一代子弹。

Med. 2024 Aug 9;5(8):856-858. doi: 10.1016/j.medj.2024.07.001.

3

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。

N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.

4

Asciminib: First Approval.阿伐替尼：首次获批。

Drugs. 2022 Feb;82(2):219-226. doi: 10.1007/s40265-021-01662-3.

5

Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML.ASCIMIB 治疗 CML 实现深度分子反应和无治疗缓解。

Int J Hematol. 2024 Oct;120(4):512-514. doi: 10.1007/s12185-024-03816-x. Epub 2024 Jul 18.

6

Asciminib in chronic myeloid leukemia: many questions still remain to be answered.阿伐替尼治疗慢性髓性白血病：仍有许多问题有待解答。

Blood Cancer J. 2021 Apr 29;11(4):81. doi: 10.1038/s41408-021-00475-7.

7

High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.阿伐替尼在肾移植后慢性肾脏病慢性髓性白血病患者中的高效性和安全性

Intern Med. 2024 Mar 1;63(5):717-720. doi: 10.2169/internalmedicine.2179-23. Epub 2023 Jul 5.

8

Asciminib as a new option in the treatment of chronic myeloid leukemia.阿塞西尼布作为慢性粒细胞白血病治疗的新选择。

Future Oncol. 2021 Dec;17(36):5003-5005. doi: 10.2217/fon-2021-1174. Epub 2021 Nov 18.

9

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.阿斯科利尼布治疗慢性髓性白血病患者在现实临床实践中的安全性和有效性。

Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.

10

Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.澳大利亚接受管理准入计划（MAP）下服用 ASCIMIB 的慢性髓性白血病患者的临床结局。

Intern Med J. 2024 Jul;54(7):1214-1218. doi: 10.1111/imj.16446. Epub 2024 Jun 17.

本文引用的文献

1

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.阿西替尼治疗新诊断的慢性髓性白血病。

N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31.